The purpose of this study is to determine the effect of gemcabene on insulin sensitivity as defined by average glucose disposal rate.

Inclusion Criteria:

• Good health, as determined by medical history, physical examination, EKG and clinical laboratory assessments
• Males; and females of non-reproductive potential
• Obesity
• Non-diabetic

Exclusion Criteria:

• Use of any medication considered unacceptable by the clinical investigators during the 14-day period before the start of Day 1. Hormone Replacement Therapy is acceptable.
• Use of a lipid-lowering agent (niacin, fibrates, statin) during the 8 weeks before screening
• Use of any anti-diabetic medications
• Use of any steroid medications
• Donation of any blood or plasma product or participation in another study in the 30 days prior to Day 1
• If female, pregnant, lactating or of childbearing potential; and
• History of significant reaction to any fibrate lipid-lowering agent